7 results about "Dihydropyrimidinuria" patented technology

The present disclosure relates to dihydropyrimidine-2,4(1H,3H)-dione-containing polycyclic compounds, or pharmaceutically acceptable salts thereof, and compositions thereof which are effective to reduce or modulate widely interspaced zinc finger motifs (WIZ) protein expression levels and / or induce fetal hemoglobin (HbF) expression, and also relates to methods of their preparation and their use in treatment of subjects in need.

Disclosed are a dihydropyrimidine based compound, a preparation method therefor and an application thereof, belonging to the technical field of pharmaceutical chemistry. The present invention relates to a dihydropyrimidine based compound, the structure of which is shown in formula I. Also provided in the present invention is an application of the compound represented by formula I, or a salt, solvate, isomer, metabolite, nitrogen oxide and prodrug thereof, in the preparation of a medicament for treating or preventing P2X3 and / or P2X2 / 3 receptor-related diseases. The dihydropyrimidine based compound of the present invention has good P2X3 receptor antagonist activity and improved safety.

The application belongs to the technical field of chemical medicine, and particularly relates to a kind of 2,3-dihydropyrimidino [4,5-d] pyrimidine-4 (1H) -ketone derivatives and preparation method and purposes thereof.The existing Wee1 small molecule inhibitors still have one or more defects in activity, safety or pharmacokinetic properties, and a new generation of Wee1 small molecule inhibitors with novel structure, low toxicity, high efficiency and excellent pharmacokinetic properties needs to be developed.The application provides a kind of 2,3-dihydropyrimidino [4,5-d] pyrimidine-4 (1H) -ketone derivatives, specifically including 95 new compounds, or pharmaceutically acceptable salt thereof, or stereoisomer thereof.Experiments show that the compound of formula (I) disclosed in the application has good inhibitory activity on Wee1, and therefore the compound of the application can be used for treating diseases caused by abnormal Wee1 activity.

The invention relates to a group of dihydropyrimidone compounds, a preparation method of the dihydropyrimidone compounds, a pharmaceutical composition containing the dihydropyrimidone compounds and application of the dihydropyrimidone compounds in pharmacy. Specifically, the compound has structures shown in general formulas (I) and (II), is used for preparing a PCSK9 inhibitor and an LDLR up-regulating agent, and has an excellent treatment effect on hyperlipidemia, fatty liver, atherosclerosis and cardiovascular and cerebrovascular diseases. The invention also relates to a pharmaceutical composition of the compound and a pharmaceutical composition for treating and / or preventing the application. The pharmaceutical composition contains an active component with a therapeutically effective amount and an optional pharmaceutically acceptable carrier.

This disclosure relates to dihydropyrimidine-2,4(1H,3H)-dione-containing polycyclic compounds or pharmaceutically acceptable salts thereof and compositions thereof that effectively reduce or regulate the expression level of broad-space zinc finger motif (WIZ) proteins and / or induce the expression of fetal hemoglobin (HbF), as well as methods for preparing them and their use in the treatment of subjects requiring them.

The application discloses a dihydropyrimidine[4,5-d]pyrimidine-2(H)-ketone Nrf2 activator and a preparation method and application thereof. The compound has the following structural general formula: experiments prove that the compound can effectively activate the Nrf2 signal pathway to produce an antioxidative stress effect, thereby protecting nerve cells, and can be used for preventing and / or treating neurodegenerative diseases.

The present disclosure relates to polycyclic compounds comprising dihydropyrimidine-2, 4 (1H, 3H)-dione, or pharmaceutically acceptable salts thereof, and compositions thereof, which are effective to reduce or modulate the expression level of the widely spaced zinc finger structure motif (WIZ) protein and / or to induce the expression of fetal hemoglobin (HbF), it also relates to methods of their preparation and their use in the treatment of subjects in need thereof.